Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP453104.RAE3v3cUzPkOxW2YauT5szLbiHYMV973MzHvEg-4XdCAY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP453104.RAE3v3cUzPkOxW2YauT5szLbiHYMV973MzHvEg-4XdCAY130_assertion type Assertion NP453104.RAE3v3cUzPkOxW2YauT5szLbiHYMV973MzHvEg-4XdCAY130_head.
- NP453104.RAE3v3cUzPkOxW2YauT5szLbiHYMV973MzHvEg-4XdCAY130_assertion description "[Thus, the growth-suppressive effect of CHK1 inhibition in BRCA2-mutant tumors can be opposed by concurrent KRAS activation and TP53 mutations typical of pancreatic adenocarcinoma, and CHK1i resistance in this setting can be overcome by gemcitabine.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP453104.RAE3v3cUzPkOxW2YauT5szLbiHYMV973MzHvEg-4XdCAY130_provenance.
- NP453104.RAE3v3cUzPkOxW2YauT5szLbiHYMV973MzHvEg-4XdCAY130_assertion evidence source_evidence_literature NP453104.RAE3v3cUzPkOxW2YauT5szLbiHYMV973MzHvEg-4XdCAY130_provenance.
- NP453104.RAE3v3cUzPkOxW2YauT5szLbiHYMV973MzHvEg-4XdCAY130_assertion SIO_000772 21289082 NP453104.RAE3v3cUzPkOxW2YauT5szLbiHYMV973MzHvEg-4XdCAY130_provenance.
- NP453104.RAE3v3cUzPkOxW2YauT5szLbiHYMV973MzHvEg-4XdCAY130_assertion wasDerivedFrom befree-20140225 NP453104.RAE3v3cUzPkOxW2YauT5szLbiHYMV973MzHvEg-4XdCAY130_provenance.
- NP453104.RAE3v3cUzPkOxW2YauT5szLbiHYMV973MzHvEg-4XdCAY130_assertion wasGeneratedBy ECO_0000203 NP453104.RAE3v3cUzPkOxW2YauT5szLbiHYMV973MzHvEg-4XdCAY130_provenance.